Phagevax creates (proposed) effective single-dose vaccine for novel h1n1 virus

PhageVax creates (proposed) effective single-dose vaccine for novel H1N1 virus
WiredPRNews.com — US based company has developed a new vaccine production method for
combating emerging infectious diseases - including the novel H1N1 swine flu and the deadly
H5N1 avian flu. These various sub-types of Influenza may merge in the 2nd and 3rd Pandemic
Waves and become easily transmissible from human to human and deadly.

Newark, Ohio July 1, 2009 – PhageVax has created a novel platform to produce vaccines
against infectious diseases - from pathogen identification to the scaled manufacture of vaccine -
in one-quarter the time as current technologies. This process allows for millions of doses to be
produced and distributed in a matter of 4 to 6 weeks for both civilian and military personnel.
Traditional vaccine generation, using eggs or other cell-culture or other insect-cell media,
typically takes from 4 to 6 months. In a time where pandemics can move around the globe at
the speed of a jetliner, the ability to develop and manufacture large amounts of vaccine quickly
is vital. A key concern is that within the time-frame of traditional vaccine manufacture the
pathogen often has mutated, thus rendering the proposed [egg-based or cell-based] vaccines
useless. Recent reports from Denmark show that the novel H1N1 was resistant to the anti-viral
called Tamiflu. This may become a trend.
PhageVax's Bacteriophage-DNA Vaccine Platform represents a "just in time" manufacturing
process for combating rapidly evolving infectious diseases. The company's platform technology
allows for production of a vaccine (from the initial identification of a pathogen to a cGMP lot of
vaccine capable of protecting tens of millions of people) in 4 to 6 weeks; literally in one-quarter
the time of traditional methods and at a fraction of the US Tax-payer's cost compared to egg-
based Flu Vaccines
Why is this important? On June 11, the World Health Organization declared a Phase Six global
novel H1N1 (swine) Flu Pandemic. A Phase Six pandemic declaration is based on the sustained
worldwide spread of said virus. In addition, it has been learned the deadly H5N1 virus involved
in the Flu outbreaks (in Egypt) is Tamiflu-resistant, although the virus was never exposed to
Tamiflu (the primary anti-viral stockpiled against a flu epidemic in the US). The novel H1N1 may
merge with the deadly H5N1 from Southeast Asia and/or merge with the deadly H5N1 from
Egypt. Each of these H5N1 viruses are distinct from each other, thus raising the complexity of
any human protection. The traditional vaccine production time-frame; flexibility; volume simply
cannot respond quickly enough to combat these unforeseen pathogenic organisms. PhageVax
has made arrangements for clinical trials at three research labs to confirm its findings and is
currently negotiating with the National Institute of Health, and the CDC and the FDA for
implementation and production of vaccines to combat swine flu, avian flu and malaria.
Research suggests that the vaccines may be sufficiently effective where one dose may protect
against infection from wild-type disease.
Clark Tibbs, CEO PhageVax, Inc. CCR CAGE CODE: 4M4V6
Phone: 740.366.9013 Fax: 740.366.5230 Cell: 740.502.9010
E-mail: [email protected]
General Offices & HQ: 855 Sharon Valley Road, Suite 101 Newark, Ohio 43055-2860 USA

Source: http://phagevax.com/wp-content/uploads/2009/07/PRESS-RELEASE-PhageVax-creates-proposed-1-dose-H1N1-Vaccine.pdf